|
PROSTVAC® - VF Synopsis (PDF)
Prostate Cancer Vaccine - Patients Brochure (PDF)
|
 |
Background on Prostate Cancer
According to the American Cancer Society, prostate cancer is one of the most common cancers affecting men in the United States, with an annual incidence of over 225,000 cases. It is estimated that the disease results in over 29,000 U.S. deaths annually. Current treatment options include surgery and radiation for localized tumors and hormone ablation therapy and chemotherapy in cases where the cancer has metastasized, or spread to other areas of the body. These treatment options carry many potential side effects, including impotence, incontinence, and loss of libido.
PROSTVAC®-VF
Therion is conducting an investigational Phase II clinical study to evaluate PROSTVAC®-VF for the treatment of men with prostate cancer who have failed hormone therapy and have evidence of metastases. PROSTVAC-VF targets prostate-specific antigen (PSA), an antigen, or protein, associated with prostate cancer. In addition to PSA, PROSTVAC-VF also incorporates TRICOM, Therion's proprietary triad of costimulatory molecules, believed to enhance and sustain a targeted immune response against tumor cells. Data from earlier studies suggest PROSTVAC-VF may induce PSA stabilization, delay time to progression, and that the vaccine is well tolerated. Data from Therion's earlier studies in prostate cancer have been published and presented in several peer-reviewed formats, many of which can be found in the Press Room section of this website.
|
